ArticleInternal and emergency medicine2025
Plasma SIRT7 as a novel biomarker for coronary artery disease and rehospitalization risk in hypertensive patients: a cross-sectional and longitudinal study.
Article in Internal and emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elevated ASGR1 as a Potential Diagnostic Biomarker for Coronary Artery Disease and Predictor of Adverse Outcomes in Hypertensive Patients.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The exact role of SIRT7 in hypertensive patients with coronary artery disease (CAD) remains elusive. This study aimed to explore plasma SIRT7 levels and their clinical significance in this population. From July 2022 to June 2024, 222 hypertensive patients (106 with isolated hypertension and 116 with hypertension plus CAD) were enrolled. Plasma SIRT7 was measured by ELISA, and participants were followed for rehospitalization (median 804 days). ROC curves, LASSO regression, and Cox proportional hazards models were used for statistical analysis. Hypertensive CAD patients had significantly higher SIRT7 levels than those without CAD (P < 0.001). Plasma SIRT7 levels were positively correlated with CK (R = 0.36, P < 0.001) and CK-MB (R = 0.50, P < 0.001), and negatively with HDL-C (R = -0.23, P < 0.001). The optimal cutoff of SIRT7 for diagnosing CAD demonstrated 94.0% sensitivity and 75.5% specificity, exhibiting an AUC of 0.917, superior to CK, CK-MB, and HDL-C. Multivariate analysis identified SIRT7 as an independent CAD risk factor (adjusted OR = 1.97, 95% CI 1.48-2.63). Restricted cubic spline (RCS) analysis revealed a linear correlation between SIRT7 and rehospitalization (P for overall = 0.038), but no non-linear relationship (P for non-linear = 0.164). Elevated SIRT7 predicted rehospitalization risk (HR = 1.15, 95% CI 1.02-1.29) and improved risk prediction, with an integrated discrimination index (IDI) of 21.8% and net reclassification improvement (NRI) of 51.0%. Plasma SIRT7 acts as both a diagnostic marker for CAD and a predictor of rehospitalization in hypertensive patients, indicating its dual role in pathogenesis and clinical monitoring. Targeting SIRT7 signaling may offer a new therapeutic strategy for hypertension-associated CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.